CGT services revenue surged 15% as clinical trial support expanded to 779 trials globally.

CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]

Moby summary of Cryoport, Inc.'s Q2 2026 earnings call

CryoPort Inc (CYRX) achieves positive adjusted EBITDA and reaffirms full-year guidance amid strong biostorage growth and expanding commercial therapy support.

CryoPort (NASDAQ:CYRX) reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million. Chief Executive Officer Jerrell Shelton said revenue momentum continue

CryoPort (CYRX) delivered earnings and revenue surprises of 0.00% and +1.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Caris Life Sciences,?Inc. (CAI) delivered earnings and revenue surprises of +100.00% and +14.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cryoport is back in focus after the modeled fair value in one framework moved from US$15.61 to US$17.06, signaling a higher price target being used in recent analysis. That shift lines up with Street research that has taken a more constructive tone on the stock, with higher targets in the mid to high teens and above US$20 tied to what analysts view as healthier trends across MVE, BioLogistics, and BioStorage. Read on to see how these updated targets fit into the evolving Cryoport narrative...